{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:28Z","timestamp":1788798448470,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["30136"],"award-info":[{"award-number":["30136"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clgc.2021.12.001","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T12:40:39Z","timestamp":1639658439000},"page":"e181-e189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)\/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Amira","family":"Awadalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-1023","authenticated-orcid":false,"given":"Mohamed H","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Abol-Enein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Rahman N","family":"Zekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-2999","authenticated-orcid":false,"given":"Mohamed Abd","family":"Elbaset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa E","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman T","family":"Hamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elsawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Shokeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.12.001_bib0001","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et\u00a0al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-387.<\/bib>","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"10.1016\/j.clgc.2021.12.001_bib0002","first-page":"550","article-title":"Molecular landscape of non-muscle invasive bladder cancer","volume":"32","author":"Meeks","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.clgc.2021.12.001_bib0003","doi-asserted-by":"crossref","first-page":"27656","DOI":"10.18632\/oncotarget.24441","article-title":"Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer","volume":"9","author":"Lee","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2021.12.001_bib0004","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/ijms18102186","article-title":"Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical Bacille Calmette-Gu\u00e9rin: a long-term follow-up study of a Japanese cohort","volume":"18","author":"Miyake","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2021.12.001_bib0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/genes8020077","article-title":"MicroRNA expression profile identifies high grade, non-muscle-invasive bladder tumors at elevated risk to progress to an invasive phenotype","volume":"8","author":"Lenherr","year":"2017","journal-title":"Genes"},{"key":"10.1016\/j.clgc.2021.12.001_bib0006","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.juro.2010.05.085","article-title":"Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer","volume":"184","author":"Alvarez-M\u00fagica","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0007","first-page":"4201","article-title":"Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer","volume":"29","author":"Cormio","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2021.12.001_bib0008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0009","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2021.12.001_bib0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.10.019","article-title":"The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non\u2013muscle-invasive bladder cancer: a preliminary results of randomized controlled trial","volume":"37","author":"Elsawy","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0012","first-page":"2479","article-title":"microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer","volume":"132","author":"Pignot","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clgc.2021.12.001_bib0013","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-19-2230","article-title":"Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction","volume":"26","author":"Kobatake","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2021.12.001_bib0014","doi-asserted-by":"crossref","first-page":"e62483","DOI":"10.1371\/journal.pone.0062483","article-title":"ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors","volume":"8","author":"Balb\u00e1s-Mart\u00ednez","year":"2013","journal-title":"Plos One"},{"key":"10.1016\/j.clgc.2021.12.001_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.04.006","article-title":"ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma","volume":"55","author":"Li","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0016","doi-asserted-by":"crossref","unstructured":"Barrows D, Feng L, Carroll TS, Allis CDJPotNAoS. Loss of UTX\/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer. 2020;117:25732-25741.","DOI":"10.1073\/pnas.2008017117"},{"key":"10.1016\/j.clgc.2021.12.001_bib0017","article-title":"ARID1A-deficiency in urothelial bladder cancer: no predictive biomarker for EZH2-inhibitor treatment response?","volume":"13","author":"Garczyk","year":"2018","journal-title":"Plus One"},{"key":"10.1016\/j.clgc.2021.12.001_bib0018","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.urolonc.2009.08.024","article-title":"A MicroRNA expression profile defining the invasive bladder tumor phenotype","volume":"29","author":"Wszolek","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0019","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/ijc.24183","article-title":"MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31","volume":"124","author":"Veerla","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2021.12.001_bib0020","unstructured":"Gui Y, Guo G, Huang Y, et\u00a0al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 2011;43:875-878."},{"key":"10.1016\/j.clgc.2021.12.001_bib0021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbrc.2018.02.051","article-title":"miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1","volume":"497","author":"Ma","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clgc.2021.12.001_bib0022","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.4161\/cc.24673","article-title":"Gene expression is highly correlated on the chromosome level in urinary bladder cancer","volume":"12","author":"LAMBROU","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clgc.2021.12.001_bib0023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11255-009-9584-3","article-title":"Up-regulation of microRNA in bladder tumor tissue is not common","volume":"42","author":"Wang","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0024","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40291-019-00410-4","article-title":"MicroRNAs: key players in bladder cancer","volume":"23","author":"Li","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.clgc.2021.12.001_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.21037\/atm.2019.02.23","article-title":"STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells","volume":"7","author":"Nie","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clgc.2021.12.001_bib0026","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.1007\/s13277-016-4894-4","article-title":"Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer","volume":"37","author":"Qiao","year":"2016","journal-title":"Tumor Biol"},{"key":"10.1016\/j.clgc.2021.12.001_bib0027","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/iju.IJU_4_17","article-title":"MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer","volume":"33","author":"Mitash","year":"2017","journal-title":"Indian J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321002317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321002317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:49Z","timestamp":1761564889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321002317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1558767321002317"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.12.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)\/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}